tirzepatide osteoarthritis GLP-1 drugs cost-effective for knee and obesity Trending now at Annals.org: Both

Nutr J 12 , 39, (2013)

They should know that: It supports cosmetic benefits due to its antioxidative properties

At week 36, the 12mg group showed the most dramatic eating behavior changes: Perceived hunger decreased by 2.4 points versus placebo Disinhibition improved by 2.6 points Dietary restraint increased by 3.3 points 100% of participants achieved at least 5% body weight loss by week 48 83% achieved 15% or greater weight loss Mean weight reduction reached 24.2% at 48 weeks These numbers represent the strongest weight loss and appetite-related outcomes ever recorded in clinical trials for any GLP-1 class medication

doi:10.1080/10408398.2015.1117413

Ambrosia Therapeutics